Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult and Adolescent Participants With Autoimmune Encephalitis

NCT07583641 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT07583641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07583641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult and Adolescent Participants With Autoimmune Encephalitis
Lead sponsor
argenx
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 1, 2027
Completion date
July 30, 2030
Enrollment
170 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune encephalitis (ae)